Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, Mizuho Analyst Says

Charles River Laboratories International (NYSE:CRL) had its price objective hoisted by Mizuho from $264.00 to $295.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Mizuho’s target price indicates a potential downside of 0.10% from the stock’s current price.

A number of other equities analysts have also recently commented on CRL. Evercore reiterated an “outperform” rating and issued a $320.00 target price on shares of Charles River Laboratories International in a report on Friday, September 11th. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Morgan Stanley boosted their target price on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Eleven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $280.31.

Charles River Laboratories International Trading Up 6.5%

Shares of NYSE CRL opened at $295.30 on Friday. Charles River Laboratories International has a 52-week low of $144.26 and a 52-week high of $303.30. The firm’s 50 day moving average price is $269.08 and its 200-day moving average price is $212.48. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The company has a market cap of $14.10 billion, a PE ratio of -60.89, a P/E/G ratio of 2.80 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the firm earned $3.12 EPS. The company’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts expect that Charles River Laboratories International will post 11.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, CAO Michael Knell sold 6,645 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting officer directly owned 11,852 shares of the company’s stock, valued at approximately $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Shannon Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the transaction, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,264,241. The trade was a 51.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 165,990 shares of company stock valued at $42,606,388 in the last three months. 1.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently bought and sold shares of CRL. QRG Capital Management Inc. boosted its position in shares of Charles River Laboratories International by 13.2% in the 2nd quarter. QRG Capital Management Inc. now owns 2,183 shares of the medical research company’s stock worth $495,000 after purchasing an additional 255 shares in the last quarter. Tidal Investments LLC increased its position in Charles River Laboratories International by 26.5% during the 2nd quarter. Tidal Investments LLC now owns 6,371 shares of the medical research company’s stock valued at $1,445,000 after buying an additional 1,334 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Charles River Laboratories International in the second quarter valued at about $172,000. NewEdge Advisors LLC raised its stake in Charles River Laboratories International by 32.6% in the second quarter. NewEdge Advisors LLC now owns 4,236 shares of the medical research company’s stock valued at $961,000 after buying an additional 1,041 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in Charles River Laboratories International by 959.9% in the second quarter. Squarepoint Ops LLC now owns 13,863 shares of the medical research company’s stock worth $3,144,000 after acquiring an additional 12,555 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: 2026 earnings outlook improved: Charles River issued EPS guidance of approximately $11.45, above the analyst consensus estimate of $11.33 and at the high end of its previously stated range. Revenue guidance of about $3.9 billion was maintained and is broadly in line with expectations. Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
• Positive Sentiment: 2030 growth targets added a longer-term catalyst: Management outlined its 2030 growth projections, which investors viewed as evidence that Charles River can expand earnings and revenue beyond the current year. The company’s outlook helped drive the stock higher and places more emphasis on execution across its research and laboratory services businesses. Charles River Laboratories Stock Rises After Unveiling 2030 Growth Targets
• Neutral Sentiment: Investor focus shifts to execution: The Investor Day presentation and transcript provided additional detail on the company’s strategy and outlook, but the long-term targets remain dependent on sustained demand, operational improvement and successful execution. Revenue expectations for 2026 were not materially above consensus. Charles River Laboratories Analyst and Investor Day Transcript

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.